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second mitochondria derived activator of caspase mimetics (SMs) is an attractive antileukemic strategy
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(TNFR2) messenger RNA expression correlates with sensitivity to SMs in primary human leukemia.
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develop strategies for the identification of leukemias with vulnerability to RIP1-dependent cell death for
tailored therapeutic interventions.
DOI: https://doi.org/10.1182/bloodadvances.2019000796





Aguadé-Gorgorió, Júlia; McComb, Scott; Eckert, Cornelia; Guinot, Anna; Marovca, Blerim; Mezzatesta,
Caterina; Jenni, Silvia; Abduli, Liridon; Schrappe, Martin; Dobay, Maria Pamela; Stanulla, Martin;
von Stackelberg, Arend; Cario, Gunnar; Bourquin, Jean-Pierre; Bornhauser, Beat C (2020). TNFR2 is
required for RIP1-dependent cell death in human leukemia. Blood advances, 4(19):4823-4833.
DOI: https://doi.org/10.1182/bloodadvances.2019000796
REGULAR ARTICLE
TNFR2 is required for RIP1-dependent cell death in human leukemia
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Key Points
• Expression of TNFR2
determines the sensi-





• TNFR2 is functionally
required for the induc-
tion of RIP1-dependent
cell death in a ligand-
independent manner.
Despitemajor advances in the treatment of patientswith acute lymphoblastic leukemia in the
last decades, refractory and/or relapsed disease remains a clinical challenge, and relapsed
leukemia patients have an exceedingly dismal prognosis. Dysregulation of apoptotic cell
deathpathways is a leading cause of drug resistance; thus, alternative cell deathmechanisms,
such as necroptosis, represent an appealing target for the treatment of high-risk
malignancies. We and other investigators have shown that activation of receptor interacting
protein kinase 1 (RIP1)–dependent apoptosis and necroptosis by second mitochondria
derived activator of caspase mimetics (SMs) is an attractive antileukemic strategy not
currently exploited by standard chemotherapy. However, the underlying molecular
mechanisms that determine sensitivity to SMs have remained elusive. We show that tumor
necrosis factor receptor 2 (TNFR2) messenger RNA expression correlates with sensitivity to
SMs in primary human leukemia. Functional genetic experiments using clustered regularly
interspaced short palindromic repeats/Cas9 demonstrate that TNFR2 and TNFR1, but not the
ligand TNF-a, are essential for the response to SMs, revealing a ligand-independent interplay
between TNFR1 and TNFR2 in the induction of RIP1-dependent cell death. Further potential
TNFR ligands, such as lymphotoxins, were not required for SM sensitivity. Instead, TNFR2
promotes the formation of a RIP1/TNFR1-containing death signaling complex that induces
RIP1 phosphorylation and RIP1-dependent apoptosis and necroptosis. Our data reveal an
alternative paradigm for TNFR2 function in cell death signaling and provide a rationale to
develop strategies for the identification of leukemias with vulnerability to RIP1-dependent
cell death for tailored therapeutic interventions.
Introduction
Patients with refractory and/or relapsed acute lymphoblastic leukemia (ALL) have a dismal prognosis.1
Dysregulation of cell death pathways leading to deficient apoptosis is widely observed in cancer and
represents a leading cause for therapy resistance and relapse in ALL.2 Although many current
approaches directly target the oncogenic lesions to resensitize to apoptosis, activating alternative
apoptosis-independent cell death mechanisms, such as necroptosis, may serve as attractive strategies
for the treatment of high-risk malignancies.3-5
Necroptosis is a recently discovered form of programmed cell death with morphological features and
genetic regulation distinct from apoptosis.6 Receptor interacting protein kinase 1 (RIP1) is a central
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regulator governing cell death by apoptosis and necroptosis, as
well as survival and inflammation through the activation of NF-kB
signaling.7When ubiquitinated by cIAP1 and cIAP2, RIP1 maintains
survival and inflammatory signaling.8,9 Upon depletion of cIAP1/
2 using second mitochondria derived activator of caspases
mimetics (SMs), deubiquitination of RIP1 activates a switch from
prosurvival to prodeath signaling. Although the role of tumor
necrosis factor receptor 1 (TNFR1) as a key upstream activator
of RIP1-mediated cell death has been well established,6 TNFR2
activation typically leads to prosurvival and proinflammatory
NF-kB signaling, and antagonizing TNFR2 has been suggested
to convey antitumor effects.10 We showed earlier that the SM
birinapant potently induces RIP1-dependent cell death by concur-
rent apoptosis and necroptosis in a subset of precursor B-cell ALL,3
and the great promise held by these agents was corroborated in
preclinical models of drug-resistant and relapsed leukemia.3,11-13
However, successful clinical translation of novel targeted therapies
requires the identification of molecular markers to preselect patients
with a high likelihood to respond. Molecular determinants to predict
sensitivity to SM are lacking, hindering clinical translation of
these compounds. Therefore, we set out to identify the molecular
mechanisms that determine sensitivity to SM as a basis to develop
strategies that are useful for further development of clinical trials.
We found TNFR2 expression to correlate with sensitivity to
birinapant in primary relapsed ALL samples and to functionally
confer sensitivity to necroptosis in a tumor necrosis factor-a
(TNF-a)–independent, but TNFR1-dependent, manner.
Material and methods
Human samples
Primary human ALL samples were cryopreserved bone marrow
aspirates of patients enrolled in the ALL-BFM 2000 and ALL-
BFM 2009 studies, as well as the ALL-REZ-BFM 2002 study for
the validation cohort. Informed consent was given in accordance
with the Declaration of Helsinki, and approval was granted by the
Ethics Commission of the Kanton Zürich (approval no. 2014-
0383). Samples were classified as standard risk, medium risk,
high risk, very high risk, morphological nonresponders, or relapse
samples, according to the clinical criteria used in the ALL-BFM
2000 study.11
Cell lines
hTERT-immortalized primary bone marrow mesenchymal stromal
cells (MSCs) were cultured in RPMI 1640 (Sigma-Aldrich; cat.
no. R0883) supplemented with 10% fetal bovine serum (Sigma-
Aldrich), 0.5% L-glutamine (Bio-Concept Laboratories), 0.5%
penicillin-streptomycin (Life Technologies), and 1 mM hydrocor-
tisone (Sigma-Aldrich; cat. no. H0888). Cells were incubated at
37°C and 5% CO2 and confirmed to be mycoplasma negative by
polymerase chain reaction (PCR).
Patient-derived xenograft experiments
Patient-derived xenograft (PDX) cells were obtained by trans-
planting 106 cells IV into 7- to 12-week-old immunodeficient NOD/
SCID/IL2rgnull (NSG) mice (male and female mice were used14).
Engrafted ALL cells were collected from the spleen. Coculture
experiments with MSCs and primary or PDX cells were performed
under serum-free conditions in AIM-V (Life Technologies; cat. no.
12055-091).15 Cells were incubated at 37°C and 5% CO2. In vivo
clustered regularly interspaced short palindromic repeats (CRISPR)
selection experiments were performed as described previously.3 In
short, 106 transduced PDX ALL cells were injected into NSG mice,
and the engraftment was monitored weekly by staining periph-
eral blood after red blood cell lysis with human CD19-PE-Cy7
and human CD45–Alexa Fluor 647 and analyzing by flow cytometry
(using a FACSCanto II flow cytometer; BD Biosciences) (see
supplemental Table 5 for all antibody clone and supplier
information). Birinapant was dissolved in 12% Captisol (Ligand
Pharmaceuticals) with 0.1% Tris at pH 6.8 and given daily by
intraperitoneal injection (30 mg/kg) during the indicated periods.
Leukemia progression was monitored weekly, as described above.
In vivo experiments were approved by the veterinary office of the
Canton of Zurich.
Viability assays
2500 hTERT MSCs were plated in serum-free AIM-V medium (Life
Technologies; cat. no. 12055-091). After 24 hours of incubation,
25 000 ALL cells were added. The cocultured cells were treated the
following day, as indicated, using an HP D300 Digital Dispenser
(Tecan). After 48 hours of treatment, live cells were stained with
CyQUANT (Life Technologies; cat. no. C35012) and quantified
using automated microscopy and multiparametric image analysis,
as described previously.3,15
Immunoprecipitation
For immunoprecipitation, 25 to 30 million PDX cells were plated
and treated, as indicated, in each case. The cells were collected,
washed with cold phosphate-buffered saline, and lysed in RIPA
buffer (150 mM NaCl, 20 mM Tris [pH 7.5], 1% NP-40, 1 mM
EDTA [pH 8.0], 0.1% sodium dodecyl sulfate [SDS]) containing
protease inhibitors (Roche Diagnostics; cat. no. 11836153001).
Twenty microliters of lysate was kept for input control, and 5 mL of
anti-TNFR1 was added to the rest. The lysates were incubated
with the antibody at 4°C overnight and subsequently incubated
with 50 mL of Dynabeads protein G (Life Technologies; cat. no.
1004D) at room temperature for 4 hours. The beads were washed
3 times with RIPA buffer, and the complex was eluted by adding
13 SDS loading buffer (62.5 nM Tris [pH 6.8], 1% SDS, 0.005%
Bromophenol Blue, 4% glycerol, 1% 2-mercaptoethanol) and
boiling at 95°C for 5 minutes.
Caspase-8 immunoprecipitation for ripoptosome analysis was
performed as described previously16 with minor modifications.
We used 20 to 25 million cells, 50 mL of protein G magnetic beads,
and 1 mg of caspase-8 antibody.
Immunoblotting
For western blotting, 3 3 105 cells were lysed in 13 SDS loading
buffer. Cell lysates were separated by SDS–polyacrylamide gel
electrophoresis (Bio-Rad; Criterion XT Precast Gels, 4% to 12%
Bis-Tris, cat. no. 345-0125) and transferred onto nitrocellulose
membranes (Bio-Rad; Trans-Blot Turbo transfer pack, cat. no. 170-
4159). Membranes were blocked with 5% nonfat milk, or 5% bovine
serum albumin in the case of cIAP2.
For the analysis of TNFR1 oligomers, western blotting was
performed in nondenaturing (samples loaded without boiling)
and nonreducing (SDS loading buffer prepared without
2-mercaptoethanol) conditions.
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Quantitative real-time PCR
RNA was extracted using an RNeasy Mini Kit (QIAGEN; cat. no.
74106). Reverse transcription was performed with MultiScribe
Reverse Transcriptase (Life Technologies; cat. no. 4311235).
Real-time PCR was performed with TaqMan Gene Expression
Master Mix (Applied Biosystems; cat. no. 436916) and the
following probes from Life Technologies: TNFRSF1A (cat. no.
Hs01042313), TNFRSF1B (cat. no. Hs00961749), cIAP2 (BIRC3;
cat. no. Hs00985031), and GAPDH (cat. no. Hs02758991). PCR
was performed using a 7900HT Fast Real-Time PCR System
(Applied Biosystems) and SDS 2.3 software. The quantification was
performed in triplicates.
Copy number variant quantitative PCR
Genomic DNA was extracted using a DNeasy Blood and Tissue Kit
(QIAGEN; cat. no. 69506). Quantitative PCR was performed using
PowerUp SYBR Green Master Mix (Life Technologies; cat. no.
A25742) and 10 ng of DNA using a forward primer ending at the
predicted CRISPR cut site (supplemental Table 3) and GAPDH as
a control. PCR was performed using a 7900HT Fast Real-Time
PCR System (Applied Biosystems) and SDS 2.3 software. The
quantification was performed in triplicates and normalized to
GAPDH.
Generation of lentiCRISPR constructs
Multicolor lentiCRISPR constructs were generated as previously
published3,17 from the lentiCRISPR v1 plasmid18 (Addgene; cat.
no. 49535). Various single guide RNA (sgRNA) sequences were
tested; the most efficient, as determined by western blotting,
were used for further experiments. The sgRNAs used for TNFR1,
TNFR2, and TNF are listed in supplemental Table 4. The sgRNAs
used for RIP1, RIP3, MLKL, caspase-8, and FADD were published
previously.3
Next-generation sequencing of CRISPR-edited loci
Genomic DNA was extracted from wild-type (WT) and TNFR2-
knockout (TNFR2ko) PDX cells using a DNeasy Blood and Tissue
Kit (QIAGEN; cat. no. 69506). A 442-bp region surrounding the
CRISPR target site was amplified by PCR using the primers
TNFR2_NGS_F and TNFR2_NGS_R (supplemental Table 3) and
Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific;
cat. no. F-530S) for subsequent amplicon deep sequencing. The
locus-specific first-step PCR products were converted into
Illumina Nextera XT libraries by second-step PCR. Subsequently,
the Illumina MiSeq platform and a v2 500 cycles kit were used to
sequence the libraries. The produced paired-end reads that
passed Illumina’s chastity filter were subject to demultiplexing and
trimming of Illumina adaptor residuals using Illumina’s real-time
analysis software (no further refinement or selection). The quality
of the reads was checked with the FastQC software (version
0.11.5; http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).
The paired-end reads were merged considering a minimum
overlap of 15 bases. Merged sequences were quality filtered,
allowing a maximum of 1 expected error per merged read and also
discarding those containing ambiguous bases. The remaining reads
were deduplicated, which means that unique sequences were
identified and clustered, retaining the information on the size of the
cluster. The cluster representatives were then globally aligned
pairwise against the genomic reference region of the first-step PCR.
Libraries and sequencing described in this section were performed
by Microsynth AG (Balgach, Switzerland). We quantified the
outcome of genome editing using CRISPResso (http://crisp-
resso.rocks) run with default parameters19 and human TNFRSF1B,
Gene ID: 7133 [NC_000001.11 (12166948..12209222)] as
reference. All results were compared with those of unedited
controls.
Generation of TNFR2 overexpression plasmid
The overexpression plasmid for TNFR2 was generated on the
pRCDRMB-EF1-MCS-2A-Bleo backbone plasmid (a gift from
Laura Lopez Garcia). IRES-GFP was cloned into the EcoRI site
using IRES-GFP forward and reverse primers and In-Fusion HD
cloning (Clontech; cat. no. 639648). The sequence for human Ig-
Flag-TNFR2 was cloned from the Ps520 plasmid (kindly provided
by Pascal Schneider) into the NheI site in the multiple cloning site
by In-Fusion HD cloning using Ig-Flag-TNFR2 forward and reverse
primers. All primers are listed in supplemental Table 3.
TNF-a ELISA
Six million PDX cells were lysed in 300 mL DISC lysis buffer (30 mM
Tris/HCl [pH 7.5], 120 mM NaCl, 10% glycerol, 1% Triton X-100)
containing complete protease inhibitors (Roche Diagnostics; cat.
no. 11836153001). TNF-a enzyme-linked immunosorbent assay
(ELISA) was performed with a human TNF-a Ready-Set-Go! ELISA
kit (cat. no. 88-7346; eBioscience). Results were extrapolated to
100 mg of total protein, quantified using a Pierce BCA Protein
Assay Kit (Thermo Fisher Scientific; cat. no. 23227).
Lentivirus production and transduction
Lentivirus was produced, as described previously,17 by transfecting
293T cells with psPAX2 (Addgene; cat. no. 12260), p.CMV.VSV.G
plasmid (Addgene; cat. no. 8454), and each plasmid (lentiCRISPR
or the TNFR2 overexpression construct) using polyethylenimine
transfection reagent (Sigma Aldrich; cat. no. 408727). The cell
supernatant was collected after 24 hours and added to the cells
with Polybrene, 8 mg/mL final concentration (Sigma-Aldrich; cat no.
H9268). Cells were incubated with the virus for 24 hours and
washed 3 times with phosphate-buffered saline before in vivo
transplantation.
Correlation of gene expression profiles and
SM response
Gene expression profiles20 were correlated with responses ((half
maximal inhibitory concentration [IC50]) to birinapant and
LCL161 using Pearson correlation. Joint correlation coefficients
were calculated from the sum of the Pearson coefficients; genes
with significant (P , .05) correlation with IC550 were arranged
as a function of decreasing joint correlation coefficients (top to
bottom) and drug response IC50 values (left to right). All gene
expression values are shown in a mean-centered and scaled heat
map (R package NMF_0.20.6).
Statistical analyses
Results are shown as mean 6 standard error of the mean (SEM)
in bar graphs and viability assays. Statistical significance was
determined with the Mann-Whitney U test using GraphPad Prism
5; values were considered significant at P , .05. For in vivo
experiments, animals were randomized, and all were included in
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the analysis. Sample sizes (n) of mice and the number of biological
repeats are indicated in the figure legends. The investigators were
blinded regarding TNFR1 and TNFR2 expression for the samples
tested in the experiment shown in Figure 2B-C.
Results
TNFR2 expression correlates with and predicts the
response to SMs in ALL
Approximately 30% of B-cell ALL (B-ALL) samples across different
risk groups respond to birinapant with an IC50# 100 nM,
3 including
a relevant proportion of very high risk and relapse cases (Figure 1A).
To identify the molecular basis for this remarkable sensitivity to
SMs in ALL3 and to identify molecular markers associated with the
response, we correlated gene expression profiles of precursor
B-ALL patient samples20 with the sensitivity to 2 SM drugs:
birinapant and LCL161. We identified TNFRSF1B (TNFR2) and
TNFRSF1A (TNFR1) among the highest correlating genes (Figure
1B-C; supplemental Figure 1A-C; supplemental Table 1). Cor-
roborating our previous results,3 the expression of RIP1, RIP3,
MLKL, or FADD did not correlate with SM activity (supplemental
Figure 1A-C). Quantitative real-time PCR confirmed the signifi-
cantly higher expression of TNFR1 and TNFR2 in responders
(IC50 # 100 nM) compared with nonresponders (IC50 . 100 nM)
(Figure 1D-E), which remained unchanged upon treatment with
birinapant (supplemental Figure 1D). Interestingly, the correlation
between expression level and sensitivity was much stronger for
TNFR2 than for TNFR1 (Figure 1D-E; supplemental Figure 1C),
with a lower variance of expression for TNFR1.
To validate the correlation of TNFR2 expression with the SM
response, we analyzed primary samples of an independent cohort
of relapsed B-ALL (supplemental Table 1), in which we detected
variable expression of TNFR1 and TNFR2 (Figure 2A; supplemental
Table 2). Primary samples with high TNFR2 expression showed
significantly higher sensitivity to birinapant compared with samples
with low TNFR2 expression (median IC50, 37.4 vs 1310 nM; P 5
.02; Figure 2B-C), with a significant inverse correlation between
TNFR2 expression and IC50 for this independent cohort (Pearson
r 5 20.71; P 5 .01) (supplemental Figure 1E). Supporting the
hypothesis that the presence of TNFR2, as well as TNFR1, may be
important for sensitivity to SM,13 1 sample with high TNFR2
expression, but very low TNFR1 expression, also showed lower
sensitivity to SM (Figure 2A-B). We confirmed the stability of
TNFR2 expression in PDX cells (supplemental Figure 1F). To
determine the cell death program activated by birinapant down-
stream of RIP1, we used the caspase inhibitor zVAD and the RIP1
kinase inhibitor necrostatin (Nec-1s) and identified that 3 of 5
samples activated a mixed phenotype of apoptosis and necroptosis,
whereas 1 sample was necroptotic and another was sensitive to
Nec-1s (Figure 2D). This distribution mirrors the phenotype
distribution that was observed previously in our primary cohort.3
Taken together, our data suggest that the messenger RNA
expression level of TNFR2 may contribute to predicting the
sensitivity of B-ALL to SM-induced RIP1-dependent death. The
combination of phenotypic drug response profiling15 and TNFR2
expression analysis suggests a potential methodology to preselect
responsive patients in a clinical setting.
TNFR1 and TNFR2 are required for the response to SM
independently of NF-kB
To determine whether TNFR2 is functionally required for SM-induced
cell death in ALL, we adapted our previously established CRISPR-
based in vivo selection methodology3 (Figure 3A). Cells from 3
PDXs were transduced with fluorescently tagged lentiCRISPR
A
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Figure 1. TNFR2 predicts SM sensitivity. (A) Sensitivity of primary ALL samples in different risk categories, according to risk stratification in the AIEOP-BFM 2000 study, to
birinapant. Numbers are cases with IC50 , 100 nM and the total analyzed cases. TNFR2 (TNFRRSF1B) expression
20 from 17 primary samples correlated with the response
(IC50) to birinapant (B) and LCL161 (C). TNFR2 (D) and TNFR1 (E) expression by quantitative real-time PCR from 12 responsive PDX samples (birinapant IC50 # 100 nM)
and 22 nonresponsive PDX samples (birinapant IC50 . 100 nM). MR/HR, medium risk/high risk; SR, standard risk; VHR, very high risk.
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constructs targeting TNFR2 or TNFR1 and transplanted into NSG
mice. Treatment of xenografted mice with birinapant selectively
enriched TNFR2-deficient leukemia cell populations (Figure 3B,F,I;
supplemental Figure 2A). Likewise, TNFR1-deficient cells were also
selected by birinapant treatment (Figure 3C,G,J), functionally
implicating TNFR1 and TNFR2 in SM-induced death. Interestingly,
TNFR1- and TNFR2-deficient cells showed a stable engraftment
before birinapant treatment, indicating that ALL does not depend on
TNFR signaling for proliferation (Figure 2B-C). In vitro drug-
response analysis of the generated knockout PDX cells (supple-
mental Figure 2B-D,E-H) corroborated that TNFR1ko and TNFR2ko
ALL were highly resistant to birinapant (Figure 3D,H,K). Importantly,
reconstitution of TNFR2 expression in TNFR2ko patient–derived
cells via lentiviral transduction of a GFP-tagged construct restored
birinapant sensitivity (Figure 2E), further supporting the requirement
for TNFR2 to activate RIP1-dependent cell death.
TNFR2 signaling can lead to activation of the canonical and
noncanonical NF-kB pathways, as well as to inhibition of the
canonical pathway through TRAF2 degradation.21 However, we
could not detect consistent differences in canonical3 (phosphor-
ylation of p65) or noncanonical NF-kB activation (as indicated by
the cleavage of p100 to p52) between responsive and non-
responsive PDX samples (supplemental Figure 3A) or between
WT and TNFR2ko PDX samples (supplemental Figure 3B).
Furthermore, inhibiting NF-kB signaling using the compound BAY
11-7082 did not influence the sensitivity of PDX samples to
birinapant (supplemental Figure 3C-E). This shows that the
sensitizing effect of TNFR2 to RIP1-dependent cell death cannot
be explained by differential activation of NF-kB signaling.
The ligand TNF-a is not required for the response
to SM
Having identified the functional requirement for TNFR1 and TNFR2
in the response to birinapant (Figure 2), we investigated the
implication of their ligand, TNF-a, in the induction of SM-induced
cell death. TNF is generally expressed at low levels in B-ALL,
regardless of birinapant sensitivity (Figure 4A) and does not
increase after birinapant treatment.3 We performed CRISPR TNF-
a knockout in PDX cells and in the supporting MSCs to generate
a TNF-a–depleted cellular system (Figure 4B-C). Despite a significant
reduction in TNF, we did not observe any effect on SM response for 3
PDX samples (Figure 4D), suggesting a TNF-a–independent
mechanism and supporting our previous findings using TNF-
a–neutralizing antibodies.3
In addition to TNF-a, other cell death ligands are known to induce
RIP1-dependent cell death.22 Therefore, we investigated the
implication of the ligands TRAIL, FasL, lymphotoxin a and b, and
their respective receptors (TRAILR1-4, Fas, and LTBR) in the
response to birinapant. Lymphotoxin was a relevant candidate
because it can interact with TNFR1 and TNFR2 when present in
the form of lymphotoxin a3 homotrimers.
22 Gene expression
analyses of 17 precursor B-ALL patient samples revealed a generally
low expression and small variance among patients for all of the
investigated genes, with the exception of TRAILR2, TRAILR4, and
LTB (Figure 4E). Neutralizing antibodies against lymphotoxin, TRAIL,
or FasL did not rescue primary ALL samples from birinapant-induced
cell death (Figure 4F), suggesting that the role of TNFR1 and TNFR2
in the response to SM is, strikingly, ligand independent.
TNFR2 promotes RIP1 recruitment to TNFR1 and cell
death without affecting TNFR1 oligomerization
Based on the requirement of TNFR1, TNFR2, and RIP1 for the
response of B-ALL to birinapant, we hypothesized that the different
levels of TNFR2 in responders and nonresponders might influence
the recruitment of RIP1 to TNFR1, as previously suggested by Chan
et al.23 Under basal unstimulated conditions, low-level interactions
between TNFR1 and RIP1 were detected as described pre-
viously in other cellular systems.24,25 After birinapant treatment,
we observed a strong recruitment of RIP1 to TNFR1 in SM-sensitive
WT ALL cells, which was diminished in TNFR2ko cells (Figure 5A;
supplemental Figure 5A). Additionally, we detected cleaved RIP1





































































































Figure 2. Validation of association between TNFR2 and sensitivity to birinapant in an independent cohort. (A) Expression of TNFR1 and TNFR2 from the validation
cohort (n 5 44), with selected patients marked in blue (high TNFR2, n 5 5) and red (low TNFR2, n 5 5). (B) Response to birinapant for selected patients (n 5 10). (C)
Birinapant IC50 values. (D) Rescue from birinapant (48 hours, 50 nM) with zVAD (25 mM) and/or Nec-1s (25 mM). All quantifications are mean 6 SEM and were derived from
1 experiment in triplicate for the indicated number of primary samples.
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Figure 3. TNFR1 and TNFR2 are required for birinapant response. (A) Schematic diagram of CRISPR in vivo selection. Total engraftment (purple) and TNFR2ko BFP-
positive (B) or TNFR1ko mCherry-positive (C) cells over the total engraftment for R-03 PDX cells. Data are representative of 3 mice per experiment. (D) In vitro birinapant
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proteolytic activity of caspase-8 (Figure 5A; supplemental Figure 5B).
Interestingly, we observed a decrease in the total amount of
TNFR1 in birinapant-responsive PDX cells after treatment that
could be rescued by inhibiting the TNF-a converting enzyme
using TAPI-0, indicating that the decrease was due to TNFR1
shedding (supplemental Figure 5C).
The recruitment of RIP1 to TNFR1 upon birinapant treatment was
confirmed in 2 more SM-sensitive PDX samples, whereas re-
cruitment was not detected in nonresponders (Figure 5B; supple-
mental Figure 5D).
Given the importance of receptor trimerization in TNFR1 signaling,
we investigated the distribution of TNFR1 into monomers, dimers,
and trimers. Interestingly, most TNFR1 exists as trimers in primary
ALL, and only a small fraction occurs in monomers (Figure 5C).
We did not observe any differences between responsive and
nonresponsive PDX samples or between WT and TNFR2ko PDX
samples (Figure 5C). Additionally, we could not detect the formation
of TNFR1 and TNFR2 heterotrimers (data not shown). Therefore,
TNFR2 promotes cell death by facilitating the recruitment of RIP1
to TNFR1, without a direct effect on TNFR1. Further supporting
a role for TNFR1 in the response to SM, phosphorylation of RIP1
at Ser166, indicative of cell death activation, was abolished in
TNFR1-deficient ALL, whereas total RIP1 was unaffected by
TNFR1 depletion (Figure 5D).
Resulting from the regulation of TNFR1-RIP1 interactions, TNFR2 is
also required for RIP1 kinase activity, as indicated by RIP1
phosphorylation at S166 in WT ALL, but not in TNFR2-deficient
ALL (Figure 5E; supplemental Figure 4E). Additionally, TNFR2 is
required for the formation of the ripoptosome, a complex containing
caspase-8 and RIP1 that mediates apoptosis and necroptosis,26 in
Figure 3. (continued) response of WT, TNFR2ko, and TNFR1ko R-03 cells treated for 48 hours. (E) In vitro birinapant response after reconstitution of TNFR2 expression in
TNFR2ko ALL cells. The same experiments were performed for PDX samples VHR-10 (E-H) and SR-13 (G-J), with 1 mouse per experiment (E-F,H-I). In vitro data (D,H,K) are












































































































































































































































Figure 4. TNF-a is not required for birinapant response. (A) TNF-a expression by quantitative real-time PCR from 12 responsive PDX samples (birinapant IC50 # 100
nM) and 22 nonresponsive PDX samples (birinapant IC50 . 100 nM). (B) Quantification of TNF-a by ELISA from cell lysates in WT and CRISPR-generated TNFko PDXs
(3 independent experiments performed in duplicates). (C) Validation of TNFko MSCs by copy number variant quantitative PCR (2 experiments performed in triplicates). (D)
Birinapant response curves for WT and TNFko PDX cells cocultured with TNFko MSCs (3 independent experiments performed in triplicates). (E) Gene expression of death
receptor ligands and receptors for 17 primary B-ALL samples. (F) Birinapant response curves for PDX samples treated with neutralizing antibodies against lymphotoxin
(LT; 0.5 mg/ml), TRAIL (10 ng/mL), and FasL (10 ng/mL) (3 independent experiments performed in triplicates). All quantifications are mean 6 SEM. R, relapse.
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Figure 5. TNFR2 promotes recruitment of RIP1 to TNFR1. (A) Endogenous TNFR1 immunoprecipitation (IP) in WT and TNFR2ko R-03 (responder) PDX cells treated
with birinapant, as indicated. (B) Lysates and TNFR1 immunoprecipitation of sensitive (R-03, IC50 , 100 nM) and resistant (VHR-01, IC50 . 1000 nM) ALL. (C) WB in
nonreducing nondenaturing conditions for TNFR1 monomers (mono), dimers, and trimers (Tri) in responder and nonresponder PDX (left panel), and WT and TNFR2ko R-03
PDX cells (right panel) treated as indicated. (D) Analysis of RIP1 phosphorylation at serine-166 (pRIP1) in WT and TNFR1ko ALL samples. (E) Lysates and caspase-8 (Casp8)
IP (ripoptosome) for WT and TNFR2ko (R2ko) R-03 and VHR-10 PDX cells treated with birinapant, as indicated. Data are representative of 3 independent experiments. Bir/bir,
birinapant; 109, 10 minutes; 309, 30 minutes.
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1 of the PDX samples that we investigated (Figure 5E, left panel).
However, its role in the formation of the ripoptosome is diverse, and
we observed steady-state ripoptosome formation that was only
mildly affected by birinapant treatment and/or TNFR2 depletion in
another PDX sample (Figure 5E, right panel).
Taken together, our results indicate a requirement of TNFR2 for cell
death upon cIAP depletion by mediating the association of RIP1
with TNFR1, which activates the TNFR1/RIP1 cell death axis and
downstream RIP1-mediated cell death. This cross talk mechanism
is the molecular basis for the exquisite response to SMs in a subset
of high-risk and relapse B-ALL cases. Thus, our data identify TNFR2
as a functionally relevant biomarker candidate that may contribute
to the identification of primary ALL with vulnerability to RIP1-
dependent cell death by SMs, together with functional approaches
(eg, ex vivo drug-response analysis).
Discussion
Impaired cell death activation is a common escape mechanism of
drug-resistant cancer cells. We showed earlier that sensitivity to
RIP1-dependent cell death is a specific vulnerability of a subgroup
of ALL, including refractory and relapsed cases, which has not been
exploited by standard chemotherapy so far.3 In particular, the
activation of RIPK3-dependent necroptosis downstream of RIP1
critically contributes to antileukemic activity,3 corroborating identi-
fication of RIPK3 as a tumor suppressor also in myeloid leukemia.27
Small molecules, such as SMs that capitalize on this vulnerability,
hold great promise for anticancer therapy. Indeed, various studies
have shown SM to have promising preclinical activity against
hematologic malignancies.3,4,12,13,28 The successful application of
novel targeted therapies for cancer treatment requires the parallel
development of robust criteria to select the patient populations who
are most likely to respond to each given therapy. Here, we show that
TNFR2 may constitute a candidate molecular marker for sensitivity
to SMs and suggest that TNFR2 gene expression analysis could be
combined with ex vivo drug sensitivity profiling15,29 to predict the
response to SMs in the setting of a clinical trial. Indeed, TNFR2 was
identified in a CRISPR-based screen as a gene conferring
sensitivity to SMs in a myeloid leukemia cell line model.30
On the functional level, our data reveal a novel ligand- and NF-
kB–independent role for TNFR2 in regulating RIP1-mediated cell
death, opening up new possibilities for therapeutic exploitation.
Although TNFR1 is expressed pleiotropically in all cells, the
expression of TNFR2 is restricted to specific cell types, including
immune cells, such as B- and T-cell subsets.31 Absence of TNFR2
might explain the low single-agent activity of SMs against many
solid tumor cell lines. In contrast, TNFR2 is increasingly identified
on subsets of primary solid tumors,10 suggesting a potential to
identify broader sensitivities to SM therapy in primary tumors.
Previous reports implicating TNFR2 in the regulation of TNF-
induced cell death described a ligand passing effect, according
to which TNFR2 could increase the concentration of TNF-a at
the cell surface and facilitate its interaction with TNFR1.32 Other
investigators described a sensitizing effect of TNFR2 caused by
degradation of TRAF2 and inhibition of the TNFR1-induced
canonical NF-kB pathway, which, in turn, lead to decreased
transcription of antiapoptotic proteins and increased TNF-
a–induced cell death.21,33 Additionally, TNFR2 stimulation has
been shown to increase TNF-a production, leading to autocrine
TNF-a signaling and cell death10,34 or to TNFR1-dependent gene
induction.34 We did not observe any consistent differences in the
activation of NF-kB that could explain the differential sensitivity.
Additionally, our data using CRISPR/Cas9-mediated deletion of
TNF-a rule out the possibility of a ligand passing effect and indicate
a TNF-a–independent role for TNFR2.
Together, our results reveal a new paradigm of receptor function
through indirect regulation of critical protein-protein interactions.
We propose a novel unexploited role for TNFR2, which primes for
cell death by promoting the association of RIP1 with TNFR1 and
subsequent cell death. This indirect regulation of cell death by
TNFR2 appears to be the underlying mechanism for its predictive
value for SM sensitivity in primary leukemia. With respect to the
further clinical development of SMs as potent antileukemia agents,
our results provide a strategy to exploit RIP1-dependent cell death
in resistant disease and support the necessity to develop functional
personalized approaches for efficient translation of novel treatment
options.
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